|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||81.77 - 83.32|
|52 Week Range||66.72 - 92.97|
|PE Ratio (TTM)||11.45|
|Dividend & Yield||3.30 (3.50%)|
|1y Target Est||N/A|
Merck and Co Inc said on Thursday the U.S. Food and Drug Administration (FDA) tentatively approved its biosimilar version of French drugmaker Sanofi SA's blockbuster diabetes treatment, Lantus. Merck's copycat, if launched, would challenge Lantus as a cheaper alternative that could chip away at the drug's sales, which reached 5.71 billion euros ($6.6 billion) last year and represented over a sixth of Sanofi's total sales.
AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).
Gaithersburg biotech Emergent BioSolutions is acquiring French pharmaceutical giant Sanofi's smallpox vaccine business in an all-cash deal worth up to $125 million. The company will pay $97.5 million up front to Sanofi and an additional $27.5 million in near-term regulatory and manufacturing milestone payments. Emergent will add the only smallpox vaccine licensed by the Food and Drug Administration to its existing portfolio of medical countermeasures to bioterrorism threats.